Keytruda pembrolizumab: Additional Phase II data

Data from 92 evaluable patients with recurrent or metastatic SCCHN who progressed on platinum-based therapy and cetuximab in the open-label Phase II KEYNOTE-055 trial showed that 200 mg IV Keytruda ev...